Clinical trial
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in…
NCT00395733 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00395733 |
|---|---|
| Title | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients |
| Official title | A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vascular Diseases |
| Intervention type | Drug |
| Interventions | Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadopentate dimeglumine (Magnevist, BAY86-4882) |
| Enrollment | 83 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Nov 3, 2006 |
| Last update posted | Dec 18, 2013 |
| Countries | China |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: